PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · IEX Real-Time Price · USD
2.370
-0.070 (-2.87%)
At close: Mar 28, 2024, 4:00 PM
2.380
+0.010 (0.42%)
After-hours: Mar 28, 2024, 6:35 PM EDT

PharmaCyte Biotech Income Statement

Millions USD. Fiscal year is May - Apr.
Year 2023202220212020201920182017201620152014 2013 - 2008
Selling, General & Admin
5.993.72.713.533.644.983.264.679.7818.66
Upgrade
Research & Development
0.470.690.920.30.4621.181.413.480.32
Upgrade
Operating Expenses
6.464.393.623.834.16.984.446.0713.2618.98
Upgrade
Operating Income
-6.46-4.39-3.62-3.83-4.1-6.98-4.44-6.07-13.26-18.98
Upgrade
Interest Expense / Income
0000000000.02
Upgrade
Other Expense / Income
-2.14-0.15-0.070-0.03-0.15--0.01-3.348.25
Upgrade
Pretax Income
-4.32-4.24-3.55-3.83-4.07-6.83-4.44-6.06-9.93-27.25
Upgrade
Net Income
-4.32-4.24-3.55-3.83-4.07-6.83-4.44-6.06-9.93-27.25
Upgrade
Shares Outstanding (Basic)
191611111100
Upgrade
Shares Outstanding (Diluted)
191611111100
Upgrade
Shares Change
25.56%971.73%60.24%23.24%13.57%14.59%12.35%6.83%20.77%32.26%
Upgrade
EPS (Basic)
-0.22-0.27-2.45-4.23--15.00-15.00-15.00-15.00-75.00
Upgrade
EPS (Diluted)
-0.22-0.27-2.45-4.23--15.00-15.00-15.00-15.00-75.00
Upgrade
Free Cash Flow
-3.79-4.12-3.33-2.34-2.88-5.08-3.34-4.35-4.56-1.55
Upgrade
Free Cash Flow Per Share
-0.20-0.27-2.30-2.59-3.92-7.87-5.93-8.66-9.71-4.00
Upgrade
EBITDA
-4.32-4.24-3.55-3.83-4.07-6.83-4.44-6.06-9.92-27.23
Upgrade
EBIT
-4.32-4.24-3.55-3.83-4.07-6.83-4.44-6.06-9.92-27.23
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).